{"id":"rituximab-eu","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"},{"rate":"10-20%","effect":"Infections"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the CD20 antigen on the surface of B cells, rituximab triggers cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity, leading to the depletion of B cells. This mechanism is particularly effective in treating B cell malignancies and autoimmune diseases.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:20.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT04268771","phase":"PHASE3","title":"A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2020-04-08","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT04680962","phase":"PHASE3","title":"MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Mabion SA","startDate":"2023-08-03","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02149121","phase":"PHASE3","title":"PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-08","conditions":"Rheumatoid Arthritis","enrollment":384},{"nctId":"NCT04671420","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.","status":"WITHDRAWN","sponsor":"Shanghai Henlius Biotech","startDate":"2020-10","conditions":"CD20-positive Follicular Lymphoma, With Low Tumour Burden","enrollment":""},{"nctId":"NCT02792699","phase":"PHASE3","title":"Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-05-17","conditions":"Arthritis, Rheumatoid","enrollment":311},{"nctId":"NCT03161457","phase":"PHASE1","title":"A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis","status":"TERMINATED","sponsor":"JHL Biotech, Inc.","startDate":"2017-02-27","conditions":"Rheumatoid Arthritis, Arthritis, Rheumatoid","enrollment":153},{"nctId":"NCT01526057","phase":"PHASE2","title":"A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03-20","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT02213263","phase":"PHASE3","title":"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09-30","conditions":"Follicular Lymphoma","enrollment":394},{"nctId":"NCT01643928","phase":"NA","title":"Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08-16","conditions":"Rheumatoid Arthritis","enrollment":185},{"nctId":"NCT01274182","phase":"PHASE1, PHASE2","title":"GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy","status":"COMPLETED","sponsor":"Sandoz","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":312},{"nctId":"NCT01390441","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MabThera®"],"phase":"phase_3","status":"active","brandName":"Rituximab (EU)","genericName":"Rituximab (EU)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}